Comparison of patient populations by treatment eras
| . | Early era . | Recent era . | P . |
|---|---|---|---|
| Cohort size | 3 713 | 5 118 | |
| Median length of follow-up, y | 10.3 | 4.6 | |
| Range | 0.1-16.1 | 0-9.1 | < .001 |
| Person-years of follow-up | 31 558 | 23 325 | |
| Median age at diagnosis of ALL, y | 4.6 | 4.7 | .8 |
| Range | 0.0-20.7 | 0-20.8 | |
| Sex, % males | 59% | 55% | < .001 |
| Cyclophosphamide dose | |||
| None | 35% | 8% | |
| 1-2 000 mg/m2 | 22% | 63% | |
| More than 2 000 mg/m2 | 43% | 29% | < .001 |
| Anthracycline dose | |||
| None | 35% | 8% | |
| 1-200 mg/m2 | 47% | 86% | |
| More than 200 mg/m2 | 18% | 6% | < .001 |
| Radiation dose | |||
| None | 49% | 72% | |
| 1 800 cGy | 49% | 25% | |
| 2 400 cGy | 2% | 3% | < .001 |
| Survival | |||
| Overall survival at 5 y | 78.7 ± 0.7% | 84.7 ± 0.5% | < .001 |
| Event-free survival at 5 y | 65.5 ± 0.8% | 74.8 ± 0.7% | < .001 |
| Cumulative incidence of second neoplasms at 5 y (95% CI) | |||
| All second neoplasms | 0.37% (0.2-0.5) | 0.43% (0.2-0.5) | .2 |
| AML | 0.17% (0.02-0.3) | 0.15% (0.03-0.3) | .4 |
| NHL | 0.06% (0-0.4) | 0.05% (0-0.1) | .2 |
| . | Early era . | Recent era . | P . |
|---|---|---|---|
| Cohort size | 3 713 | 5 118 | |
| Median length of follow-up, y | 10.3 | 4.6 | |
| Range | 0.1-16.1 | 0-9.1 | < .001 |
| Person-years of follow-up | 31 558 | 23 325 | |
| Median age at diagnosis of ALL, y | 4.6 | 4.7 | .8 |
| Range | 0.0-20.7 | 0-20.8 | |
| Sex, % males | 59% | 55% | < .001 |
| Cyclophosphamide dose | |||
| None | 35% | 8% | |
| 1-2 000 mg/m2 | 22% | 63% | |
| More than 2 000 mg/m2 | 43% | 29% | < .001 |
| Anthracycline dose | |||
| None | 35% | 8% | |
| 1-200 mg/m2 | 47% | 86% | |
| More than 200 mg/m2 | 18% | 6% | < .001 |
| Radiation dose | |||
| None | 49% | 72% | |
| 1 800 cGy | 49% | 25% | |
| 2 400 cGy | 2% | 3% | < .001 |
| Survival | |||
| Overall survival at 5 y | 78.7 ± 0.7% | 84.7 ± 0.5% | < .001 |
| Event-free survival at 5 y | 65.5 ± 0.8% | 74.8 ± 0.7% | < .001 |
| Cumulative incidence of second neoplasms at 5 y (95% CI) | |||
| All second neoplasms | 0.37% (0.2-0.5) | 0.43% (0.2-0.5) | .2 |
| AML | 0.17% (0.02-0.3) | 0.15% (0.03-0.3) | .4 |
| NHL | 0.06% (0-0.4) | 0.05% (0-0.1) | .2 |